<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ENTYVIO- vedolizumab injection, powder, lyophilized, for solution </strong><br>Takeda Pharmaceuticals America, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ENTYVIO safely and effectively. See full prescribing information for ENTYVIO.<br>ENTYVIO  (vedolizumab) for injection,  for intravenous use<br> <br>Initial U.S. Approval: 2014</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ENTYVIO is an integrin receptor antagonist indicated for: </p>
<p class="Highlighta">  </p>
<p class="Highlighta"><span class="Bold">Adult <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span> (UC) (<a href="#ID_d7a57562-16e2-4cc9-989b-0d54af6bcbdc">1.1</a>)</span> </p>
<dl>
<dt>•</dt>
<dd>Adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to a <span class="product-label-link" type="condition" conceptid="4147451" conceptname="Tumor necrosis">tumor necrosis</span> factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> on corticosteroids:<dl>
<dt>•</dt>
<dd>inducing and maintaining clinical response</dd>
<dt>•</dt>
<dd>inducing and maintaining clinical remission </dd>
<dt>•</dt>
<dd>improving endoscopic appearance of the mucosa</dd>
<dt>•</dt>
<dd>achieving corticosteroid-free remission</dd>
</dl>
</dd>
</dl>
<p class="Highlighta"><span class="Bold">Adult Crohn's Disease (CD) (<a href="#ID_16d2cd01-86cb-4031-8214-fdecb087c5e2">1.2</a>)</span> </p>
<dl>
<dt>•</dt>
<dd>Adult patients with moderately to severely active CD who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> on corticosteroids:<dl>
<dt>•</dt>
<dd>achieving clinical response </dd>
<dt>•</dt>
<dd>achieving clinical remission</dd>
<dt>•</dt>
<dd>achieving corticosteroid-free remission</dd>
</dl>
</dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Recommended dosage in UC and CD: 300 mg infused intravenously over approximately 30 minutes at zero, two and six weeks, then every eight weeks thereafter. (<a href="#ID_492251e0-7d8b-493a-8bf2-fbaa07bc4796">2.3</a>)</dd>
<dt>•</dt>
<dd>Discontinue ENTYVIO in patients who do not show evidence of therapeutic benefit by Week 14. (<a href="#ID_492251e0-7d8b-493a-8bf2-fbaa07bc4796">2.3</a>)</dd>
<dt>•</dt>
<dd>Must reconstitute ENTYVIO lyophilized powder with Sterile Water for injection and must dilute in 250 mL of sterile 0.9% Sodium Chloride injection prior to administration. See Full Prescribing Information for complete reconstitution and dilution instructions. (<a href="#ID_c0b406e6-6b42-4d16-9ac8-dd87c9225a4e">2.4</a>)</dd>
<dt>•</dt>
<dd>Administer infusion solution within four hours of reconstitution and dilution. (<a href="#ID_c0b406e6-6b42-4d16-9ac8-dd87c9225a4e">2.4</a>)</dd>
<dt>•</dt>
<dd>Bring patients up to date with all immunizations (according to current immunization guidelines) before initiating treatment with ENTYVIO. (<a href="#ID_b5dd2375-5a37-4884-8a5c-f81eef0fa6fa">2.2</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">For injection: 300 mg of lyophilized vedolizumab in a single-use 20 mL vial. (<a href="#ID_2b6d1e22-6abd-4855-81b5-a7033333c1d2">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Patients who have had a known serious or severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to ENTYVIO or any of its excipients. (<a href="#ID_e54ecfc1-c104-45a5-97be-0ca8e67c8d5a">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> (including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>)</span>:  Discontinue ENTYVIO if <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or other serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> occur. (<a href="#ID_cdcbf331-7561-469f-8719-a3166c14387c">5.1</a>)</dd>
<dt>•</dt>
<dd>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span>: Treatment with ENTYVIO is not recommended in patients with active, severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> are controlled. Consider withholding ENTYVIO in patients who develop a severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> while on treatment with ENTYVIO. (<a href="#ID_3663a90a-ea0e-4eeb-9257-75ec782b67ea">5.2</a>)</dd>
<dt>•</dt>
<dd>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">Progressive Multifocal Leukoencephalopathy</span>: </span>Although no cases have been observed in ENTYVIO clinical trials, JCV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> resulting in <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span> (PML) and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has occurred in patients treated with another integrin receptor antagonist. A risk of PML cannot be ruled out. Monitor patients for any new or worsening neurological signs or symptoms. (<a href="#_5.3_Prior_and">5.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence ≥3% and ≥1% higher than placebo): <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in extremities. (<a href="#ID_66893270-e03f-4730-8aeb-4b4d40b35b13">6.1</a>) </p>
<p class="Highlighta">  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact </span><span class="Bold">Takeda Pharmaceuticals at 1-877-TAKEDA-7 (1-877-825-3327)</span><span class="Bold"> or FDA at 1-800-FDA-1088 or </span><span class="Underline"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a></span> </p>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 5/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Adult <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Adult Crohn’s Disease</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Important Administration Instructions</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Prior to Administration of ENTYVIO</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dosage in Adults with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span> or Crohn’s Disease</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Reconstitution and Dilution Instructions</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Infusion-Related Reactions and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">Progressive Multifocal Leukoencephalopathy</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Live and Oral Vaccines</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Immunogenicity</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Natalizumab</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 TNF Blockers</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Live Vaccines</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-10.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-11" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-12.1" class="toc">14.1 Clinical Studies in <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span></a></h2>
<h2><a href="#section-12.2" class="toc">14.2 Clinical Studies in Crohn’s Disease</a></h2>
<h1><a href="#section-13" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_c0e48036-a1c6-4de5-8782-720bcd7fb171"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d7a57562-16e2-4cc9-989b-0d54af6bcbdc"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Adult <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span></h2>
<p class="First">ENTYVIO (vedolizumab) is indicated for:</p>
<dl>
<dt>•</dt>
<dd>inducing and maintaining clinical response,</dd>
<dt>•</dt>
<dd>inducing and maintaining clinical remission,</dd>
<dt>•</dt>
<dd>improving the endoscopic appearance of the mucosa, and </dd>
<dt>•</dt>
<dd>achieving corticosteroid-free remission</dd>
</dl>
<p>in adult patients with moderately to severely active <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> who have had an inadequate response with, lost response to, or were intolerant to a <span class="product-label-link" type="condition" conceptid="4147451" conceptname="Tumor necrosis">tumor necrosis</span> factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> on corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_16d2cd01-86cb-4031-8214-fdecb087c5e2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Adult Crohn’s Disease</h2>
<p class="First">ENTYVIO (vedolizumab) is indicated for:</p>
<dl>
<dt>•</dt>
<dd>achieving clinical response,</dd>
<dt>•</dt>
<dd>achieving clinical remission, and</dd>
<dt>•</dt>
<dd>achieving corticosteroid-free remission</dd>
</dl>
<p>in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to a <span class="product-label-link" type="condition" conceptid="4147451" conceptname="Tumor necrosis">tumor necrosis</span> factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> on corticosteroids.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_f593ffba-feff-48dc-a34b-4eb2d352d10e"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_843e3a77-4353-4a73-b274-7053b7252775"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Important Administration Instructions</h2>
<p class="First">Administer ENTYVIO as an intravenous infusion over 30 minutes. Do not administer as an intravenous push or bolus. ENTYVIO lyophilized powder must be reconstituted with Sterile Water for injection and diluted in 250 mL of sterile 0.9% Sodium Chloride injection prior to administration <span class="Italics">[see Dosage and Administration (<a href="#ID_c0b406e6-6b42-4d16-9ac8-dd87c9225a4e">2.4</a>)]</span>. After the infusion is complete, flush with 30 mL of sterile 0.9% Sodium Chloride injection.</p>
<p>ENTYVIO should be administered by a healthcare professional prepared to manage <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, if they occur. Appropriate monitoring and medical support measures should be available for immediate use. Observe patients during infusion and until the infusion is complete.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b5dd2375-5a37-4884-8a5c-f81eef0fa6fa"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Prior to Administration of ENTYVIO</h2>
<p class="First">Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all immunizations according to current immunization guidelines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_492251e0-7d8b-493a-8bf2-fbaa07bc4796"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dosage in Adults with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span> or Crohn’s Disease</h2>
<p class="First">The recommended dosage of ENTYVIO in adults with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> or Crohn's disease is 300 mg administered by intravenous infusion at zero, two and six weeks and then every eight weeks thereafter.</p>
<p>Discontinue therapy in patients who show no evidence of therapeutic benefit by Week 14.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c0b406e6-6b42-4d16-9ac8-dd87c9225a4e"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Reconstitution and Dilution Instructions</h2>
<p class="First"><span class="Italics"><span class="Underline">Reconstitution Instructions</span></span></p>
<p>Reconstitute ENTYVIO at room temperature. ENTYVIO should be reconstituted and prepared by a trained medical professional using aseptic technique by the following procedure:</p>
<dl>
<dt>1.</dt>
<dd>Remove the flip-off cap from the single-dose vial and wipe with alcohol swab. Reconstitute ENTYVIO vial containing lyophilized powder with 4.8 mL of Sterile Water for injection, using a syringe with a 21 to 25 gauge needle.</dd>
<dt>2.</dt>
<dd>Insert the syringe needle into the vial through the center of the stopper and direct the stream of Sterile Water for injection to the glass wall of the vial to avoid excessive foaming.</dd>
<dt>3.</dt>
<dd>Gently swirl the vial for at least 15 seconds to dissolve the lyophilized powder. <span class="Underline">Do not vigorously shake or invert</span>.</dd>
<dt>4.</dt>
<dd>Allow the solution to sit for up to 20 minutes at room temperature to allow for reconstitution and for any foam to settle; the vial can be swirled and inspected for dissolution during this time. If not fully dissolved after 20 minutes, allow another 10 minutes for dissolution. Do not use the vial if the drug product is not dissolved within 30 minutes.</dd>
<dt>5.</dt>
<dd>Visually inspect the reconstituted ENTYVIO solution for particulate matter and discoloration prior to administration. Solution should be clear or opalescent, colorless to light brownish yellow and free of visible particulates. Do not administer reconstituted solution showing uncharacteristic color or containing particulates.</dd>
<dt>6.</dt>
<dd>Prior to withdrawing the reconstituted ENTYVIO solution from the vial, gently invert vial three times.</dd>
<dt>7.</dt>
<dd>Withdraw 5 mL (300 mg) of reconstituted ENTYVIO solution using a syringe with a 21 to 25 gauge needle. Discard any remaining portion of the reconstituted solution in the vial.</dd>
</dl>
<p><span class="Italics"><span class="Underline">Dilution Instructions</span></span></p>
<p>Add the 5 mL (300 mg) of reconstituted ENTYVIO solution to 250 mL of sterile 0.9% Sodium Chloride and gently mix the infusion bag. Do not add other medicinal products to the prepared infusion solution or intravenous infusion set. Once reconstituted and diluted, use the infusion solution as soon as possible. </p>
<p><span class="Italics"><span class="Underline">Storage</span></span></p>
<p>If necessary, the infusion solution may be stored for up to four hours at 2° to 8°C (36º to 46ºF). Do not freeze. <span class="Underline">Discard any unused portion of the infusion solution</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_2b6d1e22-6abd-4855-81b5-a7033333c1d2"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"> ENTYVIO for injection: 300 mg of vedolizumab as a lyophilized cake in single dose 20 mL vials for reconstitution.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_e54ecfc1-c104-45a5-97be-0ca8e67c8d5a"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">ENTYVIO is contraindicated in patients who have had a known serious or severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to ENTYVIO or any of its excipients (such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and increased heart rate) <span class="Italics">[see Warnings and Precautions (<a href="#ID_cdcbf331-7561-469f-8719-a3166c14387c">5.1</a>) and Adverse Reactions (<a href="#ID_66893270-e03f-4730-8aeb-4b4d40b35b13">6.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_5bb80ce9-4991-44f1-b6fd-691fdaeb2874"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cdcbf331-7561-469f-8719-a3166c14387c"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Infusion-Related Reactions and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">In UC Trials I and II and CD Trials I and III, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> occurred including a case of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> (one out of 1434 patients [0.07%])<span class="Italics"> [see Adverse Reactions (<a href="#ID_66893270-e03f-4730-8aeb-4b4d40b35b13">6.1</a>)]</span>. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span> and heart rate have also been observed. The majority were mild to moderate in severity as assessed by the investigator. Experience with other biologic medications suggests that <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> to ENTYVIO may vary in their time of onset from during infusion or immediately post-infusion to occurring up to several hours post-infusion.</p>
<p>If <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or other serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> occur, discontinue administration of ENTYVIO immediately and initiate appropriate treatment (e.g., epinephrine and antihistamines).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3663a90a-ea0e-4eeb-9257-75ec782b67ea"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Patients treated with ENTYVIO are at increased risk for developing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> <span class="Italics">[see Adverse Reactions (<a href="#ID_66893270-e03f-4730-8aeb-4b4d40b35b13">6.1</a>)]</span>. The most commonly reported <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in clinical trials occurring at a rate greater on ENTYVIO than placebo involved the upper respiratory and nasal mucosa (e.g., <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>). Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> have also been reported in patients treated with ENTYVIO, including <span class="product-label-link" type="condition" conceptid="45772085" conceptname="Anal abscess">anal abscess</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> (some fatal), <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">salmonella</span> <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, Listeria <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, <span class="product-label-link" type="condition" conceptid="437202" conceptname="Giardiasis">giardiasis</span> and cytomegaloviral <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p>ENTYVIO is not recommended in patients with active, severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> are controlled. Consider withholding treatment in patients who develop a severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> while on treatment with ENTYVIO. Exercise caution when considering the use of ENTYVIO in patients with a history of recurring severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Consider screening for <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> (TB) according to the local practice. For <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span> (PML), see <span class="Italics">Warnings and Precautions (<a href="#_5.3_Liver_Injury">5.3</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_86bd61bc-5df8-4e92-b565-85c5b6228b1c"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">Progressive Multifocal Leukoencephalopathy</span></h2>
<p class="First">Another integrin receptor antagonist has been associated with <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span> (PML), a rare and often fatal <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infection</span> of the central nervous system (CNS). PML is caused by the John Cunningham (JC) virus and typically only occurs in patients who are immunocompromised.</p>
<p>In ENTYVIO clinical trials, patients were actively monitored for PML with frequent and regular screenings, and evaluations of any new, unexplained neurological symptoms, as necessary. While zero cases of PML were identified among patients with at least 24 months of exposure, a risk of PML cannot be ruled out. No claims of comparative safety to other integrin receptor antagonists can be made based on this data.</p>
<p>Monitor patients on ENTYVIO for any new onset, or worsening, of neurological signs and symptoms. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> on one side of the body or <span class="product-label-link" type="condition" conceptid="4320789" conceptname="Clumsiness">clumsiness</span> of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>. The progression of deficits usually leads to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or severe <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> over weeks or months. If PML is suspected, withhold dosing with ENTYVIO and refer to a neurologist; if confirmed, discontinue dosing permanently.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f5d74803-15ea-4e98-8714-aa06f188a9df"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span></h2>
<p class="First">There have been reports of elevations of transaminase and/or bilirubin in patients receiving ENTYVIO. In general, the combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> that may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or the need for a liver transplant in some patients. ENTYVIO should be discontinued in patients with <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or other evidence of significant <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> <span class="Italics">[see Adverse Reactions (<a href="#ID_66893270-e03f-4730-8aeb-4b4d40b35b13">6.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_af4f8ca1-fa37-4888-9130-be8cf4a37641"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Live and Oral Vaccines</h2>
<p class="First">Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all immunizations according to current immunization guidelines <span class="Italics">[see Dosage and Administration (<a href="#ID_b5dd2375-5a37-4884-8a5c-f81eef0fa6fa">2.2</a>)]</span>. Patients receiving ENTYVIO may receive non-live vaccines (e.g., <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span> vaccine injection) and may receive live vaccines if the benefits outweigh the risks. There are no data on the secondary transmission of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> by live vaccines in patients receiving ENTYVIO <span class="Italics">[see Adverse Reactions (<a href="#ID_66893270-e03f-4730-8aeb-4b4d40b35b13">6.1</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_d71e0a62-188f-4042-9fa5-9e54cad62174"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following topics are also discussed in detail in the Warnings and Precautions section:</p>
<dl>
<dt>•</dt>
<dd>Infusion-Related Reactions and Hypersensitivity Reactions<span class="Italics"> [see Warnings and Precautions (<a href="#ID_cdcbf331-7561-469f-8719-a3166c14387c">5.1</a>)]</span>
</dd>
<dt>•</dt>
<dd>Infections <span class="Italics">[see Warnings and Precautions (<a href="#ID_3663a90a-ea0e-4eeb-9257-75ec782b67ea">5.2</a>)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">Progressive Multifocal Leukoencephalopathy</span> <span class="Italics">[see Warnings and Precautions (<a href="#_5.3_Liver_Injury">5.3)</a>]</span>
</dd>
<dt>•</dt>
<dd>Liver Injury <span class="Italics">[see Warnings and Precautions (<a href="#_5.4_Liver_Injury">5.4</a>)]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_66893270-e03f-4730-8aeb-4b4d40b35b13"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The data described below reflect exposure to ENTYVIO in 3,326 patients and healthy volunteers in clinical trials, including 1,396 exposed for greater than one year, and 835 exposed for greater than two years.</p>
<p>The safety data described in <span class="Italics">Table 1</span> are derived from four controlled Phase 3 trials (UC Trials I and II, and CD Trials I and III); data from patients receiving open-label ENTYVIO treatment at Weeks 0 and 2 (prior to entry into UC Trial II and CD Trial III) and from Weeks 6 to 52 (non-responders at Week 6 of UC Trial I and CD Trial I) are included <span class="Italics">[see Clinical Studies (<a href="#ID_3d84fac7-a8fa-4a5d-a662-8a1e3708359c">14.1</a> and <a href="#ID_2e3e5a32-1a3b-4701-810f-f371a2209858">14.2</a>)</span>].</p>
<p>In these trials, 1,434 patients received ENTYVIO 300 mg for up to 52 weeks, and 297 patients received placebo for up to 52 weeks. Of these, 769 patients had <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> and 962 patients had Crohn’s disease. Patients were exposed for a mean duration of 259 days (UC Trials I and II) and 247 days (CD Trials I and III).</p>
<p>Adverse reactions were reported in 52% of patients treated with ENTYVIO and 45% of patients treated with placebo (UC Trials I and II: 49% with ENTYVIO and 37% with placebo; CD Trials I and III: 55% with ENTYVIO and 47% with placebo). Serious adverse reactions were reported in 7% of patients treated with ENTYVIO compared to 4% of patients treated with placebo (UC Trials I and II: 8% with ENTYVIO and 7% with placebo; CD Trials I and III: 12% with ENTYVIO and 9%, with placebo). </p>
<p>The most common adverse reactions (reported by ≥3% of patients treated with ENTYVIO in the UC Trials I and II and CD Trials I and III combined group and ≥1% higher than in combined placebo group) were <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in extremities <span class="Italics">(Table 1)</span>.</p>
<table>
<col width="52%">
<col width="23%">
<col width="25%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Data from patients receiving open-label ENTYVIO treatment at Weeks 0 and 2 (prior to entry into UC Trial II  and CD Trial III) and from Weeks 6 to 52 (non-responders at Week 6 of UC Trial I and CD Trial I) are included.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Patients who received ENTYVIO  for up to 52 weeks.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Patients who received placebo for up to 52 weeks.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td colspan="3" valign="bottom"><dl>
<dt> </dt>
<dd>
<span class="Bold"><span class="Underline">Table 1.  Adverse Reactions in ≥3% of ENTYVIO-treated Patients and ≥1% Higher than in Placebo (UC Trials I and II</span></span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><span class="Bold"><span class="Underline"> and CD Trials I and III</span></span><a href="#footnote-1" class="Sup">*</a><span class="Bold"><span class="Underline">)</span></span>
</dd>
</dl></td></tr>
<tr>
<td class="Botrule Lrule" valign="bottom"><dl>
<dt> </dt>
<dd><span class="Bold"><span class="Underline">Adverse Reaction</span></span></dd>
</dl></td>
<td class="Botrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold"><span class="Underline">ENTYVIO</span></span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a><span class="Underline"><span class="Bold"><br></span>(N=1434)</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold"><span class="Underline">Placebo</span></span><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a><span class="Underline"><span class="Bold"><br></span>(N=297)</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="Underline"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></span></dd>
</dl></td>
<td align="center" valign="top"><p class="First"><span class="Underline">13%</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><span class="Underline">7%</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="Underline"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></span></dd>
</dl></td>
<td align="center" valign="top"><p class="First"><span class="Underline">12%</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><span class="Underline">11%</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="Underline"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></span></dd>
</dl></td>
<td align="center" valign="top"><p class="First"><span class="Underline">12%</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><span class="Underline">10%</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="Underline"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></span></dd>
</dl></td>
<td align="center" valign="top"><p class="First"><span class="Underline">9%</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><span class="Underline">8%</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="Underline"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></span></dd>
</dl></td>
<td align="center" valign="top"><p class="First"><span class="Underline">9%</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><span class="Underline">7%</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="Underline"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span> </span></dd>
</dl></td>
<td align="center" valign="top"><p class="First"><span class="Underline">7%</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><span class="Underline">6%</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="Underline"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></span></dd>
</dl></td>
<td align="center" valign="top"><p class="First"><span class="Underline">6%</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><span class="Underline">3%</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="Underline"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></span></dd>
</dl></td>
<td align="center" valign="top"><p class="First"><span class="Underline">5%</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><span class="Underline">3%</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="Underline"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></span></dd>
</dl></td>
<td align="center" valign="top"><p class="First"><span class="Underline">4%</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><span class="Underline">3%</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="Underline"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></span></dd>
</dl></td>
<td align="center" valign="top"><p class="First"><span class="Underline">4%</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><span class="Underline">2%</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="Underline"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></span></dd>
</dl></td>
<td align="center" valign="top"><p class="First"><span class="Underline">4%</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><span class="Underline">3%</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="Underline"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></span></dd>
</dl></td>
<td align="center" valign="top"><p class="First"><span class="Underline">3%</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><span class="Underline">2%</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="Underline"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></span></dd>
</dl></td>
<td align="center" valign="top"><p class="First"><span class="Underline">3%</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><span class="Underline">1%</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="Underline"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></span></dd>
</dl></td>
<td align="center" valign="top"><p class="First"><span class="Underline">3%</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><span class="Underline">1%</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="Underline">Oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></span></dd>
</dl></td>
<td align="center" valign="top"><p class="First"><span class="Underline">3%</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><span class="Underline">1%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><dl>
<dt> </dt>
<dd><span class="Underline"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> in extremities</span></dd>
</dl></td>
<td class="Botrule" align="center" valign="top"><p class="First"><span class="Underline">3%</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Underline">1%</span></p></td>
</tr>
<tr class="Last"><td class="Toprule" colspan="3" valign="top"></td></tr>
</tbody>
</table>
<p>Safety data for patients (n=279) in UC Trials I and II and CD Trials I and III who received ENTYVIO at Weeks 0 and 2 and were then randomized to placebo at Week 6 for up to 52 weeks, and for patients (n=416) in CD Trial II, a 10 week Crohn’s disease trial, are similar to those listed in <span class="Italics">Table 1</span>.</p>
<p><span class="Italics"><span class="Underline">Infusion-Related Reactions and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></span></p>
<p>Serious infusion-related reactions and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported following ENTYVIO administration in clinical trials <span class="Italics">[see Warnings and Precautions (<a href="#ID_cdcbf331-7561-469f-8719-a3166c14387c">5.1</a>)]</span>. In UC Trials I and II and Crohn’s Trials I and III, one case of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> [one out of 1434 patients treated with ENTYVIO (0.07%)] was reported by a Crohn’s disease patient during the second infusion (symptoms reported were <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span> and heart rate) and was managed with discontinuation of infusion and treatment with antihistamine and intravenous hydrocortisone. </p>
<p>In UC Trials I and II and CD Trials I and III, 4% of patients treated with ENTYVIO and 3% of patients treated with placebo experienced an infusion-related reaction (IRR). The most frequently observed IRR in the patients treated with ENTYVIO (reported more than twice) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, infusion-related reaction, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (each of these adverse reactions occurred in &lt;1% in all patients treated with ENTYVIO) and no individual adverse reaction reported occurred at a rate above 1%.  These reactions generally occurred within the first two hours after the infusion and resolved with no treatment or following antihistamine and/or IV hydrocortisone treatment. Less than 1% of patients treated with ENTYVIO had IRRs assessed by the investigator as severe, and IRRs requiring discontinuation of study treatment occurred in &lt;1%.</p>
<p>In clinical trials, for patients with mild IRRs or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, physicians were allowed to pretreat with standard medical treatment (e.g., antihistamine, hydrocortisone and/or acetaminophen) prior to next infusion.</p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></span></p>
<p>In UC Trials I and II and CD Trials I and III, the rate of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> was 0.85 per patient-year in the patients treated with ENTYVIO and 0.7 per patient-year in the patients treated with placebo <span class="Italics">[see Warnings and Precautions (<span class="Underline"><a href="#ID_3663a90a-ea0e-4eeb-9257-75ec782b67ea">5.2</a></span>)]</span>. The <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> consisted primarily of <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>. Two percent of patients discontinued ENTYVIO due to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>In UC Trials I and II and CD Trials I and III, the rate of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> was 0.07 per patient-year in patients treated with ENTYVIO and 0.06 per patient-year in patients treated with placebo. Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were more common in Crohn’s disease patients than <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> patients, and <span class="product-label-link" type="condition" conceptid="45772085" conceptname="Anal abscess">anal abscesses</span> were the most frequently reported serious adverse reaction in Crohn’s disease patients. Over 48 months, there was no increase in the rate of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>In controlled- and open-label long-term extension trials in adults treated with ENTYVIO, serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> have been reported, including <span class="product-label-link" type="condition" conceptid="45772085" conceptname="Anal abscess">anal abscess</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> (some fatal), <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">salmonella</span> <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, Listeria <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, <span class="product-label-link" type="condition" conceptid="437202" conceptname="Giardiasis">giardiasis</span> and cytomegaloviral <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p>In UC Trials I and II and CD Trials I and III, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, including <span class="product-label-link" type="condition" conceptid="4000938" conceptname="Bacterial sepsis">bacterial sepsis</span> and <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>, was reported in four of 1434 (0.3%) patients treated with ENTYVIO and in two of 297 patients treated with placebo (0.7%). During these trials, two Crohn’s disease patients treated with ENTYVIO died due to reported <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> or <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>; both of these patients had significant comorbidities and a complicated hospital course that contributed to the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. In an open label long-term extension trial, additional cases of <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> (some fatal), including <span class="product-label-link" type="condition" conceptid="4000938" conceptname="Bacterial sepsis">bacterial sepsis</span> and <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>, were reported. The rate of <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> in patients with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> or Crohn’s disease receiving ENTYVIO was two per 1000 patient-years.</p>
<p>In clinical trials, all patients were screened for <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>. One case of latent, <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> was diagnosed during the controlled trials with ENTYVIO. Additional cases of <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> were diagnosed during the open-label trial. All of these observed cases occurred outside the United States, and none of the patients had extrapulmonary manifestations.</p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span></span></span></p>
<p>There have been reports of elevations of transaminase and/or bilirubin in patients receiving ENTYVIO <span class="Italics">[see Warnings and Precautions (<a href="#_5.4_Liver_Injury">5.4</a>)]</span>. In UC Trials I and II and CD Trials I and III, three patients reported serious adverse reactions of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, manifested as elevated transaminases with or without elevated bilirubin and symptoms consistent with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (e.g., <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>). These adverse reactions occurred following two to five ENTYVIO doses; however, based on case report information it is unclear if the reactions indicated drug-induced or autoimmune etiology. All patients recovered following discontinuation of therapy with some requiring corticosteroid treatment. In controlled trials, the incidence of ALT and AST elevations ≥3 x ULN was &lt;2% in patients treated with ENTYVIO and in patients treated with placebo. In the open-label trial, one additional case of serious <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> was observed. </p>
<p><span class="Italics"><span class="Underline">Malignancies</span></span></p>
<p>In UC Trials I and II and CD Trials I and III, malignancies (excluding <span class="product-label-link" type="condition" conceptid="4093447" conceptname="Dysplasia">dysplasia</span> and basal cell carcinoma) were reported in six of 1434 (0.4%) patients treated with ENTYVIO, including colon cancer (n=2), transitional cell carcinoma (n=1), breast cancer (n=1), <span class="product-label-link" type="condition" conceptid="437238" conceptname="Carcinoid tumor of appendix">carcinoid tumor of the appendix</span> (n=1) and squamous cell carcinoma (n=1). Malignancy was reported in one of 297 (0.3%) patients treated with placebo (squamous cell carcinoma).</p>
<p>Malignancies (excluding <span class="product-label-link" type="condition" conceptid="4093447" conceptname="Dysplasia">dysplasia</span> and basal cell carcinoma) observed during the ongoing open-label long-term extension trial included B-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, breast cancer, colon cancer, <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">malignant hepatic neoplasm</span>, malignant <span class="product-label-link" type="condition" conceptid="4128888" conceptname="Neoplasm of lung">lung neoplasm</span>, malignant melanoma, lung cancer of primary <span class="product-label-link" type="condition" conceptid="4102373" conceptname="Neuroendocrine carcinoma">neuroendocrine carcinoma</span>, <span class="product-label-link" type="condition" conceptid="196653" conceptname="Malignant tumor of kidney">renal cancer</span> and squamous cell carcinoma. Overall, the number of malignancies in the clinical trials was small; however, long-term exposure was limited.</p>
<p><span class="Italics"><span class="Underline">Live and Oral Vaccines</span></span></p>
<p>There are no data on the secondary transmission of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> by live vaccines in patients receiving ENTYVIO.</p>
<p>In a placebo-controlled study of healthy volunteers, 61 subjects were given a single ENTYVIO 750 mg dose (2.5 times the recommended dose), and 62 subjects received placebo followed by intramuscular vaccination with <span class="product-label-link" type="condition" conceptid="4318957" conceptname="Hepatitis B surface antigen">Hepatitis B surface antigen</span> and oral <span class="product-label-link" type="condition" conceptid="198677" conceptname="Cholera">cholera</span> vaccine. After intramuscular vaccination with three doses of recombinant <span class="product-label-link" type="condition" conceptid="4318957" conceptname="Hepatitis B surface antigen">Hepatitis B surface antigen</span>, those treated with ENTYVIO did not have lower rates of protective immunity to <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B virus. However, those exposed to ENTYVIO did have lower seroconversion rates and anti-<span class="product-label-link" type="condition" conceptid="198677" conceptname="Cholera">cholera</span> titers relative to placebo after receiving the two doses of a killed, oral <span class="product-label-link" type="condition" conceptid="198677" conceptname="Cholera">cholera</span> vaccine. The impact on other oral vaccines and on nasal vaccines in patients is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f9532657-9e50-48db-beb9-19d03acd6220"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Immunogenicity</h2>
<p class="First">As with all therapeutic proteins, there is potential for immunogenicity. In UC Trials I and II and CD Trials I and III, in patients who received ENTYVIO, the frequency of antibodies detected in patients was 13% at 24 weeks after the last dose of study drug (greater than five half-lives after last dose). During treatment, 56 of 1434 (4%) of patients treated with ENTYVIO had detectable anti-vedolizumab antibody at any time during the 52 weeks of continuous treatment. Nine of 56 patients were persistently positive (at two or more study visits) for anti-vedolizumab antibody and 33 of 56 patients developed neutralizing antibodies to vedolizumab. Among eight of these nine subjects with persistently positive anti-vedolizumab antibody and available vedolizumab concentration data, six had undetectable and two had reduced vedolizumab concentrations <span class="Italics">[see Clinical Pharmacology (<a href="#ID_b7354d8a-d2e3-4d6b-b10e-0f73a2b78d62">12.3</a>)]</span>. None of the nine subjects with persistently positive anti-vedolizumab antibody achieved clinical remission at Weeks 6 or 52 in the controlled trials.</p>
<p>The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including sample handling, timing of sample collection, concomitant medications, presence of vedolizumab, and underlying disease. For these reasons, comparison of the incidence of antibodies to ENTYVIO with the incidence of antibodies to other products may be misleading.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_4bdf9aff-ec51-4e29-9f15-21ec6c8c05c3"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6f940dfe-ad19-413c-a13d-9840d186209f"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Natalizumab</h2>
<p class="First">Because of the potential for increased risk of PML and other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, avoid the concomitant use of ENTYVIO with natalizumab.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a017cf71-e448-4ae2-a4ba-09a5671d8e21"></a><a name="section-7.2"></a><p></p>
<h2>7.2 TNF Blockers</h2>
<p class="First">Because of the potential for increased risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, avoid the concomitant use of ENTYVIO with TNF blockers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a814f34a-dbff-4053-8b2a-7ca84f3041e8"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Live Vaccines</h2>
<p class="First">Live vaccines may be administered concurrently with ENTYVIO only if the benefits outweigh the risks <span class="Italics">[see Warnings and Precautions (<a href="#_5.5_Live_and">5.5</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_4abd56a8-4c18-47ca-8c17-d8a34a44217f"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_61b7bd34-24b7-4b8e-a20d-23a115afbe5e"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Underline">Pregnancy Exposure Registry</span></p>
<p>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ENTYVIO during pregnancy. Information about the registry can be obtained by calling 1-877-TAKEDA7 (1-877-825-3327).</p>
<p><span class="Underline"><span class="Italics">Pregnancy Category B</span>:</span></p>
<p><span class="Underline">Risk Summary</span></p>
<p>There are no studies with ENTYVIO in pregnant women. No fetal harm was observed in animal reproduction studies with intravenous administration of vedolizumab to rabbits and monkeys at dose levels 20 times the recommended human dosage. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the benefits to the mother outweigh the risk to the unborn child.</p>
<p><span class="Underline">Clinical Considerations</span></p>
<p>Any adverse pregnancy effect from ENTYVIO would likely be greater during the second and third trimesters of pregnancy. Monoclonal antibodies are transported across the placenta in a linear fashion as pregnancy progresses, with the largest amount transferred during the third trimester.</p>
<p><span class="Underline">Animal Data</span></p>
<p>A reproduction study has been performed in pregnant rabbits at single intravenous doses up to 100 mg/kg administered on gestation Day 7 (about 20 times the recommended human dosage) and has revealed no evidence of impaired fertility or harm to the fetus due to vedolizumab. A pre- and post-natal development study in monkeys showed no evidence of any adverse effect on pre- and post-natal development at intravenous doses up to 100 mg/kg (about 20 times the recommended human dosage).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_0cb10f51-caf5-4627-be0c-5827d4f3cd5d"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is unknown whether vedolizumab is present in human milk. Vedolizumab was detected in the milk of lactating monkeys. Exercise caution when administering vedolizumab to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_75fd35c2-2d3a-47e3-9c77-fa02defc4bb3"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<dl>
<dt> </dt>
<dd>Safety and effectiveness of ENTYVIO in pediatric patients have not been established.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_887bc39b-7acd-47e1-877c-9ea9f0fe3bfd"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<dl>
<dt> </dt>
<dd>Clinical trials of ENTYVIO did not include sufficient numbers of subjects aged 65 and over (46 Crohn’s and <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> patients aged 65 and over were treated with ENTYVIO during controlled Phase 3 trials) to determine whether they respond differently from younger subjects. However, no overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_49e762a0-6a60-43ae-b6f5-f4a89055a7d7"></a><a name="section-9"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">ENTYVIO (vedolizumab), an integrin receptor antagonist, is a humanized IgG<span class="Sub">1</span> monoclonal antibody produced in Chinese hamster ovary cells that binds to the human α4β7 integrin. ENTYVIO has an approximate molecular weight of 147 kilodaltons.</p>
<p>ENTYVIO is supplied as a sterile, white to off-white, preservative-free, lyophilized cake for intravenous infusion. After reconstitution with 4.8 mL Sterile Water for Injection, USP, the resulting pH is approximately 6.3.</p>
<p>Each single-use vial contains 300 mg vedolizumab, 23 mg L-histidine, 21.4 mg L-histidine monohydrochloride, 131.7 mg L-arginine hydrochloride, 500 mg sucrose and 3 mg polysorbate 80.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_3ec4c5cf-16df-4c2e-b406-5350c8c4c4a5"></a><a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_2c605433-5506-43e7-bbbd-4a3ef45bef6d"></a><a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Vedolizumab is a humanized monoclonal antibody that specifically binds to the α4β7 integrin and blocks the interaction of α4β7 integrin with mucosal addressin cell <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesion</span> molecule-1 (MAdCAM-1) and inhibits the migration of memory T-<span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> across the endothelium into inflamed gastrointestinal parenchymal tissue. Vedolizumab does not bind to or inhibit function of the α4β1 and αEβ7 integrins and does not antagonize the interaction of α4 integrins with vascular cell <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesion</span> molecule-1 (VCAM-1). </p>
<p>The α4β7 integrin is expressed on the surface of a discrete subset of memory T-<span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> that preferentially migrate into the gastrointestinal tract. MAdCAM-1 is mainly expressed on gut endothelial cells and plays a critical role in the homing of T-<span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> to gut lymph tissue. The interaction of the α4β7 integrin with MAdCAM-1 has been implicated as an important contributor to the chronic <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> that is a hallmark of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> and Crohn’s disease.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_8420b5dd-09f9-4fb5-a254-687e7265cfe6"></a><a name="section-10.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">In clinical trials with ENTYVIO at doses ranging from 0.2 to 10 mg/kg (which includes doses outside of the recommended dose), saturation of α4β7 receptors on subsets of circulating <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> involved in gut-immune surveillance was observed.</p>
<p>In clinical trials with ENTYVIO at doses ranging from 0.2 to 10 mg/kg and 180 to 750 mg (which include doses outside of the recommended dose) in healthy subjects and in patients with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> or Crohn’s disease, vedolizumab did not elevate <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>, <span class="product-label-link" type="condition" conceptid="4172647" conceptname="Basophil count">basophils</span>, eosinophils, B-helper and cytotoxic T-<span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, total memory helper T-<span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, monocytes or natural killer cells.</p>
<p>A reduction in <span class="product-label-link" type="condition" conceptid="437915" conceptname="Gastrointestinal mucositis">gastrointestinal inflammation</span> was observed in rectal biopsy specimens from Phase 2 <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> patients exposed to ENTYVIO for four or six weeks compared to placebo control as assessed by histopathology.</p>
<p>In a study of 14 healthy subjects, ENTYVIO did not affect the CD4+ lymphocyte cell counts, CD8+ lymphocyte cell counts, or the CD4+:CD8+ ratios in the CSF <span class="Italics">[see Clinical Pharmacology (<a href="#ID_b7354d8a-d2e3-4d6b-b10e-0f73a2b78d62">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_b7354d8a-d2e3-4d6b-b10e-0f73a2b78d62"></a><a name="section-10.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Similar pharmacokinetics were observed in <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> and Crohn’s disease patients administered 300 mg ENTYVIO as a 30 minute intravenous infusion on Weeks 0 and 2, followed by 300 mg ENTYVIO every eight weeks starting from Week 6 <span class="Italics">(Table 2)</span>.</p>
<table>
<col width="33%">
<col width="26%">
<col width="50%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Data from patients in UC Trials I and II and CD Trials I and III with pharmacokinetic data available; data from patients with anti-vedolizumab antibody were excluded.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>Steady-state trough serum concentration.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule" colspan="3" valign="middle"><p class="First"><span class="Bold">Table 2.  Mean ± SD Vedolizumab Concentrations in Patients<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a> with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span> and Crohn’s Disease </span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="middle"><p class="First"><span class="Bold">Patient Population</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Weeks 0 to 6</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Weeks 6 to 52</span></p>
<p>ENTYVIO Every 8 Weeks</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">Trough Serum Concentration at Week 6 (mcg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">Trough Serum Concentration</p>
<p>at Week 46<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a> (mcg/mL)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First">26.3 ± 12.9</p>
<p>(N=210)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">11.2 ± 7.2</p>
<p>(N=77)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Crohn’s Disease</p></td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First">27.4 ± 19.2</p>
<p>(N=198)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">13.0 ± 9.1</p>
<p>(N=72)</p>
</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="3" valign="middle"></td></tr>
</tbody>
</table>
<p>The presence of persistent anti-vedolizumab antibody was observed to substantially reduce serum concentrations of vedolizumab, either to undetectable or negligible levels at Weeks 6 and 52 (n=8).</p>
<p>Vedolizumab clearance depends on both linear and nonlinear pathways; the nonlinear clearance decreases with increasing concentrations. Population pharmacokinetic analyses indicated that the linear clearance was approximately 0.157 L/day, the serum half-life was approximately 25 days at 300 mg dosage, and the distribution volume was approximately 5 L.</p>
<p>Vedolizumab was not detected in the cerebrospinal fluid (CSF) of 14 healthy subjects at five weeks after a single intravenous administration of 450 mg ENTYVIO (1.5 times the recommended dosage).</p>
<p><span class="Italics"><span class="Underline">Special Populations</span></span></p>
<p>Population pharmacokinetic analysis showed that the severity of disease state, body weight, prior treatment with TNF blocker therapy, age (18 to 78 years), serum albumin, co-administered immunomodulators (including azathioprine, 6-mercaptopurine, methotrexate), and co-administered aminosalicylates did not have a clinically meaningful effect on the pharmacokinetics of ENTYVIO.</p>
<p>Pharmacokinetics of vedolizumab in patients with renal or <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> have not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_40c30ee8-3ea1-4cf5-83fd-2ebe7e5cc579"></a><a name="section-11"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_97a31924-d150-4f7e-8e34-5772e3691ca3"></a><a name="section-11.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals have not been performed to evaluate the carcinogenic potential of vedolizumab. Studies to evaluate the possible impairment of fertility or mutagenic potential of vedolizumab have not been performed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_a0b34f18-b2a1-4ce7-ad73-0f2f10b46ef9"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3d84fac7-a8fa-4a5d-a662-8a1e3708359c"></a><a name="section-12.1"></a><p></p>
<h2>14.1 Clinical Studies in <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span></h2>
<p class="First">The safety and efficacy of ENTYVIO were evaluated in two randomized, double-blind, placebo-controlled trials (UC Trials I and II) in adult patients with moderately to severely active <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> (UC) defined as Mayo score of six to 12 with endoscopy subscore of two or three. The Mayo score ranges from zero to 12 and has four subscales that are each scored from zero (normal) to three (most severe): stool frequency, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>, findings on endoscopy, and physician global assessment. An endoscopy subscore of two is defined by marked <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, lack of vascular pattern, friability, and erosions; an endoscopy subscore of three is defined by spontaneous <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and ulceration.</p>
<p>Enrolled patients in the United States (US) had over the previous five-year period an inadequate response or intolerance to immunomodulator therapy (i.e., azathioprine or 6-mercaptopurine) and/or an inadequate response, loss of response, or intolerance to a TNF blocker. Outside the US, prior treatment with corticosteroids was sufficient for entry if over the previous five-year period the patients were corticosteroid dependent (i.e., unable to successfully taper corticosteroids without a return of the symptoms of UC) or had an inadequate response or intolerance to corticosteroids.</p>
<p>Patients that had received natalizumab ever in the past, and patients that had received a TNF blocker in the past 60 days were excluded from enrollment. Concomitant use of natalizumab or a TNF blocker was not allowed.</p>
<p><span class="Italics"><span class="Underline">UC Trial I</span></span></p>
<p>In UC Trial I, 374 patients were randomized in a double-blind fashion (3:2) to receive ENTYVIO 300 mg or placebo by intravenous infusion at Week 0 and Week 2. Efficacy assessments were at Week 6. Concomitant stable dosages of aminosalicylates, corticosteroids (prednisone dosage ≤30 mg/day or equivalent), and immunomodulators (azathioprine or 6‑mercaptopurine) were permitted through Week 6.</p>
<p>At baseline, patients received corticosteroids (54%), immunomodulators (azathioprine or 6-mercaptopurine) (30%), and/or aminosalicylates (74%). Thirty-nine percent of patients had an inadequate response, loss of response, or intolerance to a TNF blocker therapy. Eighteen percent of patients had an inadequate response, inability to taper or intolerance to prior corticosteroid treatment only (i.e., had not received prior immunomodulators or TNF blockers). The median baseline Mayo score was nine in the ENTYVIO group and eight in the placebo group.</p>
<p>In UC Trial I, a greater percentage of patients treated with ENTYVIO compared to patients treated with placebo achieved clinical response at Week 6 (defined in <span class="Italics">Table 3</span>). A greater percentage of patients treated with ENTYVIO compared to patients treated with placebo also achieved clinical remission at Week 6 (defined in <span class="Italics">Table 3</span>). In addition, a greater percentage of patients treated with ENTYVIO had improvement of endoscopic appearance of the mucosa at Week 6 (defined in <span class="Italics">Table 3</span>).</p>
<table>
<col width="42%">
<col width="13%">
<col width="14%">
<col width="12%">
<col width="25%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Clinical response: reduction in complete Mayo score of ≥3 points and ≥30% from baseline with an accompanying decrease in <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span> subscore of ≥1 point or absolute <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span> subscore of ≤1 point.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>Clinical remission: complete Mayo score of ≤2 points and no individual subscore &gt;1 point.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd>Improvement of endoscopic appearance of the mucosa: Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, decreased vascular pattern, mild friability).</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule" colspan="5" valign="top"><p class="First"><span class="Bold">Table 3.  Proportion of Patients Meeting Efficacy Endpoints at Week 6 (UC Trial I)</span></p></td></tr>
<tr>
<td class="Botrule Toprule" valign="bottom"><p class="First"><span class="Bold">Endpoint</span></p></td>
<td class="Botrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Placebo<br></span>N=149</p></td>
<td class="Botrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">ENTYVIO<br></span>N=225</p></td>
<td class="Botrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">p-value</span></p></td>
<td class="Botrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Treatment Difference</span></p>
<p><span class="Bold">and</span></p>
<p><span class="Bold">95% CI</span></p>
</td>
</tr>
<tr>
<td class="Toprule" valign="middle"><p class="First">Clinical response<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a> at Week 6</p></td>
<td class="Toprule" align="center" valign="middle"><p class="First">26%</p></td>
<td class="Toprule" align="center" valign="middle"><p class="First">47%</p></td>
<td class="Toprule" align="center" valign="middle"><p class="First">&lt;0.001</p></td>
<td class="Toprule" align="center" valign="middle">
<p class="First">22%</p>
<p>(12%, 32%)</p>
</td>
</tr>
<tr>
<td valign="middle"><p class="First">Clinical remission<a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a> at Week 6</p></td>
<td align="center" valign="middle"><p class="First">5%</p></td>
<td align="center" valign="middle"><p class="First">17%</p></td>
<td align="center" valign="middle"><p class="First">0.001</p></td>
<td align="center" valign="middle">
<p class="First">12%</p>
<p>(5%, 18%)</p>
</td>
</tr>
<tr>
<td class="Botrule" valign="middle"><p class="First">Improvement of endoscopic appearance of the mucosa<a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a> at Week 6</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">25%</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">41%</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">0.001</p></td>
<td class="Botrule" align="center" valign="middle">
<p class="First">16%</p>
<p>(6%, 26%)</p>
</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="5" valign="top"><p class="First"><span class="Italics"></span></p></td></tr>
</tbody>
</table>
<p><span class="Italics"><span class="Underline">UC Trial II</span></span></p>
<p>In order to be randomized to treatment in UC Trial II, patients had to have received ENTYVIO and be in clinical response at Week 6. Patients could have come from either UC Trial I or from a group who received ENTYVIO open-label.</p>
<p>In UC Trial II, 373 patients were randomized in a double‑blind fashion (1:1:1) to one of the following regimens beginning at Week 6: ENTYVIO 300 mg every eight weeks, ENTYVIO 300 mg every four weeks or placebo every four weeks. Efficacy assessments were at Week 52. Concomitant aminosalicylates and corticosteroids were permitted through Week 52. Concomitant immunomodulators (azathioprine or 6-mercaptopurine) were permitted outside the US but were not permitted beyond Week 6 in the US. </p>
<p>At Week 6, patients were receiving corticosteroids (61%), immunomodulators (azathioprine or 6-mercaptopurine) (32%) and aminosalicylates (75%). Thirty-two percent of patients had an inadequate response, loss of response or intolerance to a TNF blocker therapy. At Week 6, the median Mayo score was eight in the ENTYVIO every eight week group, the ENTYVIO every four week group, and the placebo group. Patients who had achieved clinical response at Week 6 and were receiving corticosteroids were required to begin a corticosteroid-tapering regimen at Week 6.</p>
<p>In UC Trial II, a greater percentage of patients in groups treated with ENTYVIO as compared to placebo achieved clinical remission at Week 52, and maintained clinical response (clinical response at both Weeks 6 and 52) <span class="Italics">(Table 4)</span>. In addition, a greater percentage of patients in groups treated with ENTYVIO as compared to placebo were in clinical remission at both Weeks 6 and 52, and had improvement of endoscopic appearance of the mucosa at Week 52 <span class="Italics">(Table 4)</span>. In the subgroup of patients who achieved clinical response at Week 6 and were receiving corticosteroid medication at baseline, a greater proportion of patients in groups treated with ENTYVIO as compared to placebo discontinued corticosteroids and were in clinical remission at Week 52 <span class="Italics">(Table 4)</span>.</p>
<p>The ENTYVIO every four week dosing regimen did not demonstrate additional clinical benefit over the every eight dosing week regimen.  The every four week dosing regimen is not the recommended dosing regimen <span class="Italics">[see Dosage and Administration (<a href="#ID_492251e0-7d8b-493a-8bf2-fbaa07bc4796">2.3</a>)]</span>.</p>
<table>
<col width="45%">
<col width="12%">
<col width="15%">
<col width="12%">
<col width="21%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Patients must have achieved clinical response at Week 6 to continue into UC Trial II.  This group includes patients that were not in clinical remission at Week 6.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>The placebo group includes those patients who received ENTYVIO at Week 0 and Week 2 and were randomized to receive placebo from Week 6 through Week 52.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">‡</a></dt>
<dd>Improvement of endoscopic appearance of the mucosa: Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, decreased vascular pattern, mild friability) at Week 52.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">§</a></dt>
<dd>Corticosteroid-free clinical remission: Assessed in the subgroup of patients who were receiving corticosteroids at baseline and who were in clinical response at Week 6 (n=72 for placebo and n=70 for ENTYVIO every eight weeks).  Corticosteroid-free clinical remission was defined as the proportion of patients in this subgroup that discontinued corticosteroids by Week 52 and were in clinical remission at Week 52.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td colspan="5" valign="middle"><p class="First"><span class="Bold">Table 4.  Proportion of Patients Meeting Efficacy Endpoints at Week 52</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a><span class="Bold"> (UC Trial II)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Endpoint</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a><span class="Bold"><br></span>N=126</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">ENTYVIO<br>Every 8 Weeks<br></span>N=122</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">p-value</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Treatment Difference</span></p>
<p><span class="Bold">and<br>95% CI</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Clinical remission at Week 52</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">16%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">42%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">&lt;0.001</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">26%</p>
<p>(15%, 37%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Clinical response at both Weeks 6 and 52</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">24%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">57%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">&lt;0.001</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">33%</p>
<p>(21%, 45%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Improvement of endoscopic appearance of the mucosa<a name="footnote-reference-11" href="#footnote-11" class="Sup">‡</a>at Week 52</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">20%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">52%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">&lt;0.001</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">32%</p>
<p>(20%, 44%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Clinical remission at both Weeks 6 and 52</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">9%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">21%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0.008</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">12%</p>
<p>(3%, 21%)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Corticosteroid-free clinical remission<a name="footnote-reference-12" href="#footnote-12" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">14%<a href="#footnote-12" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">31%<a href="#footnote-12" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0.012</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">18%</p>
<p>(4%, 31%)</p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2e3e5a32-1a3b-4701-810f-f371a2209858"></a><a name="section-12.2"></a><p></p>
<h2>14.2 Clinical Studies in Crohn’s Disease</h2>
<p class="First">The safety and efficacy of ENTYVIO were evaluated in three randomized, double-blind, placebo-controlled clinical trials (CD Trials I, II, and III) in adult patients with moderately to severely active Crohn’s disease (CD) (Crohn’s Disease Activity Index [CDAI] score of 220 to 450).<span class="Sup">1</span></p>
<p>Enrolled patients in the United States (US) had over the previous five-year period an inadequate response or intolerance to immunomodulator therapy (i.e., azathioprine, 6-mercaptopurine, or methotrexate) and/or an inadequate response, loss of response, or intolerance to one or more TNF blockers. Outside the US, prior treatment with corticosteroids was sufficient for entry if over the previous five-year period the patients were corticosteroid dependent (i.e., unable to successfully taper corticosteroids without a return of the symptoms of CD) or had an inadequate response or intolerance to corticosteroids.</p>
<p>Patients that had received natalizumab ever in the past, and patients that had received a TNF blocker in the past 30 to 60 days were excluded from enrollment. Concomitant use of natalizumab or a TNF blocker was not allowed.</p>
<p><span class="Italics"><span class="Underline">CD Trial I</span></span></p>
<p>In CD Trial I, 368 patients were randomized in a double-blind fashion (3:2) to receive ENTYVIO 300 mg or placebo by intravenous infusion at Week 0 and Week 2. Efficacy assessments were at Week 6. Concomitant stable dosages of aminosalicylates, corticosteroids (prednisone dosage ≤30 mg/day or equivalent), and immunomodulators (azathioprine, 6-mercaptopurine or methotrexate) were permitted through Week 6.</p>
<p>At baseline, patients were receiving corticosteroids (49%), immunomodulators (azathioprine, 6-mercaptopurine, or methotrexate) (35%), and/or aminosalicylates (46%). Forty-eight percent of the patients had an inadequate response, loss of response, or intolerance to a TNF blocker therapy. Seventeen percent of patients had inadequate response, inability to taper, or intolerance to prior corticosteroid treatment only (i.e., had not received prior immunomodulators or TNF blockers). The median baseline CDAI score was 324 in the ENTYVIO group and 319 in the placebo group.</p>
<p>In CD Trial I, a statistically significantly higher percentage of patients treated with ENTYVIO achieved clinical remission (defined as CDAI ≤150) as compared to placebo at Week 6 (<span class="Italics">Table 5</span>). The difference in the percentage of patients who demonstrated clinical response (defined as a ≥100-point decrease in CDAI score from baseline), was however, not statistically significant at Week 6. </p>
<p><span class="Italics"><span class="Underline">CD Trial II</span></span></p>
<p>Compared to CD Trial I, CD Trial II enrolled a higher number of patients who had over the previous five-year period had an inadequate response, loss of response, or intolerance to one or more TNF blockers (76%); this was the primary analysis population. In CD Trial II, 416 patients were randomized in a double-blind fashion (1:1) to receive either ENTYVIO 300 mg or placebo at Weeks 0, 2 and 6. Efficacy assessments were at Weeks 6 and 10. Concomitant aminosalicylates, corticosteroids, and immunomodulators (azathioprine, 6-mercaptopurine, or methotrexate) were permitted through Week 10.</p>
<p>At baseline, patients were receiving corticosteroids (54%), immunomodulators (azathioprine, 6-mercaptopurine, or methotrexate) (34%), and aminosalicylates (31%). The median baseline CDAI score was 317 in the ENTYVIO group and 301 in the placebo group.</p>
<p>For the primary endpoint (clinical remission at Week 6), treatment with ENTYVIO did not result in statistically significant improvement over placebo (<span class="Italics">Table 5</span>). Secondary endpoints including assessments at Week 10 were not tested because the primary endpoint was not statistically significant. </p>
<table>
<col width="39%">
<col width="18%">
<col width="19%">
<col width="14%">
<col width="18%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd>Clinical Remission: CDAI  ≤150</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">†</a></dt>
<dd>Adjusted p-value for multiple comparisons of two primary endpoints</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">‡</a></dt>
<dd>The primary analysis population for CD Trial II was patients that had an inadequate response, loss of response, or intolerance to one or more TNF blockers (76% of the overall population)</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">§</a></dt>
<dd>NS: Not significant (Secondary endpoints including assessments at Week 10 were not tested because the CD Trial II primary endpoint was not statistically significant)</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td colspan="5" valign="middle"><p class="First"><span class="Bold">Table 5.  Proportion of Patients in Clinical Remission at Week 6 (CD Trials I and II)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">ENTYVIO</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">p-value</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Treatment Difference</span></p>
<p><span class="Bold">and</span></p>
<p><span class="Bold">95% CI</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle">
<p class="First">CD Trial I:</p>
<p>Clinical Remission<a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a>at Week 6</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">7%</p>
<p>(10/148)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">15%</p>
<p>(32/220)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0.041<a name="footnote-reference-14" href="#footnote-14" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">8%</p>
<p>(1%, 14%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle">
<p class="First">CD Trial II<a name="footnote-reference-15" href="#footnote-15" class="Sup">‡</a>:</p>
<p>Clinical Remission<a href="#footnote-13" class="Sup">*</a> at Week 6</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">12%</p>
<p>(19/157)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">15%</p>
<p>(24/158)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">NS<a name="footnote-reference-16" href="#footnote-16" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">3%</p>
<p>(-5%, 11%)</p>
</td>
</tr>
<tr class="Last"><td colspan="5" valign="middle"></td></tr>
</tbody>
</table>
<p><span class="Italics"><span class="Underline">CD Trial III</span></span></p>
<p>In order to be randomized to treatment in CD Trial III, patients had to have received ENTYVIO and be in clinical response (defined as a ≥70-point decrease in CDAI score from baseline) at Week 6. Patients could have come from either CD Trial I or from a group who received ENTYVIO open-label. </p>
<p>In CD Trial III, 461 patients were randomized in a double‑blind fashion (1:1:1) to one of the following regimens beginning at Week 6: ENTYVIO 300 mg every eight weeks, ENTYVIO 300 mg every four weeks or placebo every four weeks. Efficacy assessments were at Week 52. Concomitant aminosalicylates and corticosteroids were permitted through Week 52. Concomitant immunomodulators (azathioprine, 6-mercaptopurine, or methotrexate) were permitted outside the US but were not permitted beyond Week 6 in the US. </p>
<p>At Week 6, patients were receiving corticosteroids (59%), immunomodulators (azathioprine, 6-mercaptopurine, or methotrexate) (31%), and aminosalicylates (41%). Fifty-one percent of patients had an inadequate response, loss of response, or intolerance to a TNF blocker therapy. At Week 6, the median CDAI score was 322 in the ENTYVIO every eight week group, 316 in the ENTYVIO every four week group, and 315 in the placebo group. Patients who had achieved clinical response (≥70 decrease in CDAI score from baseline) at Week 6 and were receiving corticosteroids were required to begin a corticosteroid-tapering regimen at Week 6. </p>
<p>In CD Trial III a greater percentage of patients in groups treated with ENTYVIO as compared to placebo were in clinical remission (defined as CDAI score ≤150) at Week 52.  A greater percentage of patients in groups treated with ENTYVIO as compared to placebo had a clinical response (defined as ≥100 decrease in CDAI score from baseline) at Week 52 <span class="Italics">(Table 6)</span>. In the subgroup of patients who were receiving corticosteroids at baseline and who were in clinical response at Week 6 (defined as ≥70 decrease in CDAI score from baseline), a greater proportion of patients in groups treated with ENTYVIO as compared to placebo discontinued corticosteroids by Week 52 and were in clinical remission at Week 52 <span class="Italics">(Table 6</span>). </p>
<p>The ENTYVIO every four week dosing regimen did not demonstrate additional clinical benefit over the every eight dosing week regimen.  The every four week dosing regimen is not the recommended dosing regimen <span class="Italics">[see Dosage and Administration (<a href="#ID_492251e0-7d8b-493a-8bf2-fbaa07bc4796">2.3)</a>]</span>.</p>
<table>
<col width="34%">
<col width="14%">
<col width="14%">
<col width="12%">
<col width="22%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-17" href="#footnote-reference-17">*</a></dt>
<dd>This group includes patients that were not in clinical remission at Week 6.  Patients must have achieved clinical response (defined as ≥70 decrease in CDAI from baseline) at Week 6 to continue into CD Trial III.</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">†</a></dt>
<dd>The placebo group includes those patients who received ENTYVIO at Week 0 and Week 2, and were randomized to receive placebo from Week 6 through Week 52</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">‡</a></dt>
<dd>Clinical remission: CDAI ≤150</dd>
<dt><a name="footnote-20" href="#footnote-reference-20">§</a></dt>
<dd>Clinical response: ≥100 decrease in CDAI from baseline</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">¶</a></dt>
<dd>Corticosteroid-free clinical remission: Assessed in the subgroup of patients who were receiving corticosteroids at baseline and who were in clinical response (defined as ≥70 decrease in CDAI from baseline) at Week 6 (n=82 for placebo and n=82 for ENTYVIO every eight weeks). Corticosteroid-free clinical remission was defined as the proportion of patients in this subgroup that discontinued corticosteroids by Week 52 and were in clinical remission at Week 52.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td colspan="5" valign="top"><p class="First"><span class="Bold">Table 6.  Proportion of Patients Meeting Efficacy Endpoints at Week 52</span><a name="footnote-reference-17" href="#footnote-17" class="Sup">*</a><span class="Bold"> (CD Trial III)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Placebo</span><a name="footnote-reference-18" href="#footnote-18" class="Sup">†</a><span class="Bold"><br></span>N=153</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">ENTYVIO<br>Every 8 Weeks<br></span>N=154</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">p-value</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Treatment Difference</span></p>
<p><span class="Bold">and</span></p>
<p><span class="Bold">95% CI</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Clinical remission<a name="footnote-reference-19" href="#footnote-19" class="Sup">‡</a> at Week 52</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">22%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">39%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0.001</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">17%</p>
<p>(7%, 28%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Clinical response<a name="footnote-reference-20" href="#footnote-20" class="Sup">§</a>at Week 52</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">30%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">44%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0.013</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">13%</p>
<p>(3%, 24%)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First">Corticosteroid-free clinical remission<a name="footnote-reference-21" href="#footnote-21" class="Sup">¶</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">16%<a href="#footnote-21" class="Sup">¶</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">32%<a href="#footnote-21" class="Sup">¶</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0.015</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">16%</p>
<p>(3%, 29%)</p>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID_09a8be28-2d38-4d30-b223-f739f27cb0d0"></a><a name="section-13"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Best WR, Becktel JM, Singleton JW, Kern F: Development of a Crohn’s Disease Activity Index, National Cooperative Crohn’s Disease Study. Gastroenterology 1976; 70(3): 439-444</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_20ef8a37-dcfd-4eea-8441-4b97af85cc8b"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">ENTYVIO (vedolizumab) is supplied in sterile 20 mL single-use glass vials, containing 300 mg of vedolizumab as a white to off-white cake.</p>
<table>
<col width="25%">
<col width="45%">
<tbody class="Headless"><tr class="First Last">
<td valign="top"><p class="First">NDC 64764-300-20</p></td>
<td valign="top"><p class="First">300 mg single-dose vial in individual carton</p></td>
</tr></tbody>
</table>
<p>Refrigerate unopened vials at 2° to 8°C (36º to 46ºF).  Retain in original package to protect from light.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_d5ea052c-86c3-43e4-81fe-e9ff41e4d6cc"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (Medication Guide).</p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></span></p>
<p>Instruct patients to report immediately if they experience symptoms consistent with a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> during or  following an infusion of ENTYVIO <span class="Italics">[see Warnings and Precautions (<a href="#ID_cdcbf331-7561-469f-8719-a3166c14387c">5.1</a>)]</span>.</p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></span></p>
<p>Inform patients that they may be more likely to develop <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> when taking ENTYVIO. Instruct patients to tell their healthcare provider if they develop any signs or symptoms of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span><span class="Italics"> [see Warnings and Precautions (<a href="#ID_3663a90a-ea0e-4eeb-9257-75ec782b67ea">5.2</a>)]</span>.</p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">Progressive Multifocal Leukoencephalopathy</span></span></span></p>
<p>Inform patients that <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span> (PML) has occurred in patients who received a different integrin receptor antagonist product. Instruct patients to report if they experience any new onset or worsening of neurological signs and symptoms immediately, as these could be indicative of PML <span class="Italics">[see Warnings and Precautions (<a href="#_5.3_Liver_Injury">5.3</a>)]</span>.</p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span></span></span></p>
<p>Inform patients that elevated transaminase levels with or without elevated bilirubin has occurred in patients who received ENTYVIO. Instruct patients to report promptly any symptoms that may indicate <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, including <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, right <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">upper abdominal discomfort</span>, dark urine or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#_5.4_Liver_Injury">5.4)</a></span><span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID_9da565f7-3e89-4b03-afde-741e452e347d"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">ENTYVIO  (en ti’ vee oh)</span></p>
<p><span class="Bold">(vedolizumab)</span></p>
<p><span class="Bold">What is the most important information I should know about ENTYVIO?</span></p>
<p><span class="Bold">ENTYVIO may cause serious side effects, including: </span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Infusion and serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</span> These reactions can happen while you are receiving ENTYVIO or several hours after treatment. You may need treatment if you have an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. Tell your healthcare provider or get medical help right away if you get any of these symptoms during or after an infusion of ENTYVIO: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your lips, tongue throat or face, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4141161" conceptname="Hot">feeling hot</span>, or <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> (feel like your heart is racing).</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>.</span> ENTYVIO may increase your risk of getting a serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Before receiving ENTYVIO and during treatment with ENTYVIO, tell your healthcare provider if you think you have an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or have symptoms of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, red or painful skin or sores on your body, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> during urination.</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">Progressive Multifocal Leukoencephalopathy</span> (PML)</span>. Although it has not been reported with ENTYVIO, it may be possible for a person to get <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span> (PML) (a rare, serious brain <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by a virus). People with weakened immune systems can get PML. PML can result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or severe <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. There is no known treatment, prevention, or cure for PML. Tell your healthcare provider right away if you have any of the following symptoms: <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or problems thinking, loss of balance, change in the way you walk or talk, decreased strength or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> on one side of the body, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, or <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>. </dd>
<dt>•</dt>
<dd>
<span class="Bold">Liver Problems</span>. Liver problems can happen in people who receive ENTYVIO.  Tell your healthcare provider right away if you have any of the following symptoms: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, loss of appetite, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on the right side of your stomach (abdomen), dark urine, or yellowing of the skin and eyes (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>).</dd>
</dl>
<p>See <span class="Bold">“What are the possible side effects of ENTYVIO??</span> for more information about side effects.</p>
<p><span class="Bold">What is ENTYVIO?</span></p>
<p>ENTYVIO is a prescription medicine used in adults:</p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">with moderate to severe active <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> (UC) when certain other UC medicines have not worked well enough or cannot be tolerated:</span><dl>
<dt>o</dt>
<dd>to begin helping some of your symptoms </dd>
<dt>o</dt>
<dd>in people who respond to ENTYVIO, to help get UC under control  (induce remission) and keep UC under control (maintain remission)</dd>
<dt>o</dt>
<dd>for people who respond to ENTYVIO, you may be able to reduce or stop the use of corticosteroid medicines</dd>
<dt>o</dt>
<dd>to improve the way the lining of your large intestine looks to your healthcare provider during colonoscopy</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">with moderate to severe active Crohn’s disease when certain other Crohn’s disease medicines have not worked well enough or cannot be tolerated:</span><dl>
<dt>o</dt>
<dd>to begin helping some of your symptoms</dd>
<dt>o</dt>
<dd>in people who respond to ENTYVIO, to help get Crohn’s disease under control (achieve remission)</dd>
<dt>o</dt>
<dd>for people who respond to ENTYVIO, you may be able to reduce or stop the use of corticosteroid medicines</dd>
</dl>
</dd>
</dl>
<p>It is not known if ENTYVIO is safe and effective in children under 18 years of age.</p>
<p><span class="Bold">Who should not receive ENTYVIO?</span></p>
<p><span class="Bold">Do not receive ENTYVIO if you</span> have had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to ENTYVIO or any of the ingredients in ENTYVIO. See the end of this Medication Guide for a complete list of ingredients in ENTYVIO.</p>
<p><span class="Bold">Before receiving ENTYVIO, tell your healthcare provider about all of your medical conditions, including if you:</span></p>
<dl>
<dt>•</dt>
<dd>have an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, think you may have an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or have <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that keep coming back <span class="Bold">(see “What is the most important information I should know about ENTYVIO??).</span>
</dd>
<dt>•</dt>
<dd>have liver problems</dd>
<dt>•</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> (TB) or have been in close contact with someone with TB. </dd>
<dt>•</dt>
<dd>have recently received or are scheduled to receive a vaccine. Talk to your healthcare provider about bringing your vaccines up-to-date before starting treatment with ENTYVIO.</dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant. It is not known if ENTYVIO will harm your unborn baby. Tell your healthcare provider right away if you become pregnant while receiving ENTYVIO.</dd>
<dt>•</dt>
<dd>are breastfeeding or plan to breastfeed. It is not known if ENTYVIO passes into your breast milk.</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and over-the-counter medicines, vitamins and herbal supplements. Especially tell your healthcare provider if you take or have recently taken Tysabri (natalizumab), a <span class="product-label-link" type="condition" conceptid="4147451" conceptname="Tumor necrosis">Tumor Necrosis</span> Factor (TNF) blocker medicine, a medicine that weakens your immune system (immunosuppressant), or corticosteroid medicine.</p>
<p><span class="Bold">How will I receive ENTYVIO?</span></p>
<dl>
<dt>•</dt>
<dd>ENTYVIO is given through a needle placed in a vein (intravenous infusion) in your arm.</dd>
<dt>•</dt>
<dd>ENTYVIO is given to you over a period of about 30 minutes.</dd>
<dt>•</dt>
<dd>Your healthcare provider will monitor you during and after the ENTYVIO infusion for side effects to see if you have a reaction to the treatment.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of ENTYVIO?</span></p>
<p><span class="Bold">ENTYVIO may cause serious side effects, </span>See<span class="Bold"> “What is the most important information I should know about ENTYVIO??</span></p>
<p><span class="Bold">The most common side effects of ENTYVIO include:</span> <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the nose and throat, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, flu, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinus infection</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">throat pain</span>, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in extremities.</p>
<p>These are not all of the possible side effects of ENTYVIO.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">General information about ENTYVIO</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about ENTYVIO that is written for health professionals. Do not use ENTYVIO for a condition for which it was not prescribed. </p>
<p><span class="Bold">What are the ingredients in ENTYVIO?</span></p>
<p>Active ingredient: vedolizumab</p>
<p>Inactive ingredients: L-histidine, L-histidine monohydrochloride, L-arginine hydrochloride, sucrose and polysorbate 80</p>
<p>Distributed by:</p>
<p><span class="Bold">Takeda Pharmaceuticals America, Inc.</span></p>
<p>Deerfield, IL 60015</p>
<p>U.S. License No.  1898</p>
<p>For more information, go to <a href="http://www.ENTYVIO.com">www.ENTYVIO.com</a> or call 1-877-825-3327</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Issued:  May 2014</p>
<p>ENTYVIO is a trademark of Millennium Pharmaceuticals Inc. and is used under license by Takeda Pharmaceuticals America, Inc.</p>
<p>All other trademark names are the property of their respective owners.</p>
<p>©2014 Takeda Pharmaceuticals America, Inc.</p>
<p>VMB245 R1</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_14a0bdc2-2381-44e2-b954-45ce169bcd2f"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL – 300 MG<br><span class="Bold">NDC </span>64764-300-20<br>Rx only<br><span class="Bold">Entyvio</span><br>vedolizumab<br>for injection<br>300 mg per vial*<br>ATTENTION: Each patient is required to receive the enclosed Medication Guide.<br>For Intravenous Use Only<br>Must be reconstituted and diluted prior <br>to use<br>Single Use Vial – Discard Unused Portion</h1>
<span class="Bold"><div class="Figure">
<a name="id870852276"></a><img alt="C:\Users\KnollMP\Pictures\1-6-11.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6e94621c-1a95-4af9-98d1-52b9e6f1949c&amp;name=6e94621c-1a95-4af9-98d1-52b9e6f1949c-01.jpg">
</div></span>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ENTYVIO 		
					</strong><br><span class="contentTableReg">vedolizumab injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-300</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VEDOLIZUMAB</strong> (VEDOLIZUMAB) </td>
<td class="formItem">VEDOLIZUMAB</td>
<td class="formItem">300 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem">23 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HISTIDINE MONOHYDROCHLORIDE</strong></td>
<td class="formItem">21.4 mg  in 5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ARGININE HYDROCHLORIDE</strong></td>
<td class="formItem">131.7 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">500 mg  in 5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">3 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-300-20</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125476</td>
<td class="formItem">05/20/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Takeda Pharmaceuticals America, Inc.
							(830134016)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6e94621c-1a95-4af9-98d1-52b9e6f1949c</div>
<div>Set id: 6e94621c-1a95-4af9-98d1-52b9e6f1949c</div>
<div>Version: 1</div>
<div>Effective Time: 20140522</div>
</div>
</div> <div class="DistributorName">Takeda Pharmaceuticals America, Inc.</div></p>
</body></html>
